- 
             Je něco špatně v tomto záznamu ?
 
Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties
E. Potůčková, K. Hrušková, J. Bureš, P. Kovaříková, IA. Špirková, K. Pravdíková, L. Kolbabová, T. Hergeselová, P. Hašková, H. Jansová, M. Macháček, A. Jirkovská, V. Richardson, DJ. Lane, DS. Kalinowski, DR. Richardson, K. Vávrová, T. Šimůnek,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
 NLK 
   
      Directory of Open Access Journals
   
    od 2006
   
      Free Medical Journals
   
    od 2006
   
      Public Library of Science (PLoS)
   
    od 2006
   
      PubMed Central
   
    od 2006
   
      Europe PubMed Central
   
    od 2006
   
      ProQuest Central
   
    od 2006-12-01
   
      Open Access Digital Library
   
    od 2006-10-01
   
      Open Access Digital Library
   
    od 2006-01-01
   
      Open Access Digital Library
   
    od 2006-01-01
   
      Medline Complete (EBSCOhost)
   
    od 2008-01-01
   
      Nursing & Allied Health Database (ProQuest)
   
    od 2006-12-01
   
      Health & Medicine (ProQuest)
   
    od 2006-12-01
   
      Public Health Database (ProQuest)
   
    od 2006-12-01
   
      ROAD: Directory of Open Access Scholarly Resources
   
    od 2006
    
- MeSH
- aldehydy chemie farmakologie toxicita MeSH
- antioxidancia chemie farmakologie MeSH
- buněčné linie MeSH
- chelátory železa chemie farmakologie MeSH
- hydrazony chemie farmakologie toxicita MeSH
- lidé MeSH
- MFC-7 buňky MeSH
- myoblasty účinky léků MeSH
- oxidační stres účinky léků MeSH
- peroxid vodíku toxicita MeSH
- protinádorové látky chemie toxicita MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, tridentate iron chelator with marked anti-oxidant and modest cytotoxic activity against neoplastic cells. However, it has poor stability in an aqueous environment due to the rapid hydrolysis of its hydrazone bond. In this study, we synthesized a series of new SIH analogs (based on previously described aromatic ketones with improved hydrolytic stability). Their structure-activity relationships were assessed with respect to their stability in plasma, iron chelation efficacy, redox effects and cytotoxic activity against MCF-7 breast adenocarcinoma cells. Furthermore, studies assessed the cytotoxicity of these chelators and their ability to afford protection against hydrogen peroxide-induced oxidative injury in H9c2 cardiomyoblasts. The ligands with a reduced hydrazone bond, or the presence of bulky alkyl substituents near the hydrazone bond, showed severely limited biological activity. The introduction of a bromine substituent increased ligand-induced cytotoxicity to both cancer cells and H9c2 cardiomyoblasts. A similar effect was observed when the phenolic ring was exchanged with pyridine (i.e., changing the ligating site from O, N, O to N, N, O), which led to pro-oxidative effects. In contrast, compounds with long, flexible alkyl chains adjacent to the hydrazone bond exhibited specific cytotoxic effects against MCF-7 breast adenocarcinoma cells and low toxicity against H9c2 cardiomyoblasts. Hence, this study highlights important structure-activity relationships and provides insight into the further development of aroylhydrazone iron chelators with more potent and selective anti-neoplastic effects.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010697
- 003
- CZ-PrNML
- 005
- 20170426102624.0
- 007
- ta
- 008
- 160408s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0112059 $2 doi
- 024 7_
- $a 10.1371/journal.pone.0112059 $2 doi
- 035 __
- $a (PubMed)25393531
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Potůčková, Eliška $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic. $7 xx0153394
- 245 10
- $a Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties / $c E. Potůčková, K. Hrušková, J. Bureš, P. Kovaříková, IA. Špirková, K. Pravdíková, L. Kolbabová, T. Hergeselová, P. Hašková, H. Jansová, M. Macháček, A. Jirkovská, V. Richardson, DJ. Lane, DS. Kalinowski, DR. Richardson, K. Vávrová, T. Šimůnek,
- 520 9_
- $a Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, tridentate iron chelator with marked anti-oxidant and modest cytotoxic activity against neoplastic cells. However, it has poor stability in an aqueous environment due to the rapid hydrolysis of its hydrazone bond. In this study, we synthesized a series of new SIH analogs (based on previously described aromatic ketones with improved hydrolytic stability). Their structure-activity relationships were assessed with respect to their stability in plasma, iron chelation efficacy, redox effects and cytotoxic activity against MCF-7 breast adenocarcinoma cells. Furthermore, studies assessed the cytotoxicity of these chelators and their ability to afford protection against hydrogen peroxide-induced oxidative injury in H9c2 cardiomyoblasts. The ligands with a reduced hydrazone bond, or the presence of bulky alkyl substituents near the hydrazone bond, showed severely limited biological activity. The introduction of a bromine substituent increased ligand-induced cytotoxicity to both cancer cells and H9c2 cardiomyoblasts. A similar effect was observed when the phenolic ring was exchanged with pyridine (i.e., changing the ligating site from O, N, O to N, N, O), which led to pro-oxidative effects. In contrast, compounds with long, flexible alkyl chains adjacent to the hydrazone bond exhibited specific cytotoxic effects against MCF-7 breast adenocarcinoma cells and low toxicity against H9c2 cardiomyoblasts. Hence, this study highlights important structure-activity relationships and provides insight into the further development of aroylhydrazone iron chelators with more potent and selective anti-neoplastic effects.
- 650 _2
- $a aldehydy $x chemie $x farmakologie $x toxicita $7 D000447
- 650 _2
- $a protinádorové látky $x chemie $x toxicita $7 D000970
- 650 _2
- $a antioxidancia $x chemie $x farmakologie $7 D000975
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrazony $x chemie $x farmakologie $x toxicita $7 D006835
- 650 _2
- $a peroxid vodíku $x toxicita $7 D006861
- 650 _2
- $a chelátory železa $x chemie $x farmakologie $7 D007502
- 650 _2
- $a MFC-7 buňky $7 D061986
- 650 _2
- $a myoblasty $x účinky léků $7 D032446
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hrušková, Kateřina $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Bureš, Jan $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Kovaříková, Petra $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Špirková, Iva A $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Pravdíková, Kateřina $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Kolbabová, Lucie $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Hergeselová, Tereza $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Hašková, Pavlína $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Jansová, Hana $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Macháček, Miloslav $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Jirkovská, Anna $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Richardson, Vera $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
- 700 1_
- $a Lane, Darius J R $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
- 700 1_
- $a Kalinowski, Danuta S $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
- 700 1_
- $a Richardson, Des R $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
- 700 1_
- $a Vávrová, Kateřina $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Šimůnek, Tomáš $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 11 (2014), s. e112059
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25393531 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20170426102943 $b ABA008
- 999 __
- $a ok $b bmc $g 1114126 $s 935065
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 9 $c 11 $d e112059 $e 20141113 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20160408
